Answers are grounded in this paper and cite their sources.
This multicenter case-control study establishes sFlt-1/PlGF ratio cutoff values for diagnosing preeclampsia, indicating improved diagnostic accuracy across gestational ages.
Background Preeclampsia occurs in 5-7% of all pregnancies and is one of the leading causes of maternal morbidity. The purpose of this multicenter case-control study was to derive the sFlt-1/PlGF ratio cutoff values in terms of sensitivity and specificity to rule-in and rule-out preeclampsia in early gestation age (20-33 6/7 weeks) and late gestation age (34+ weeks), including pregnant female patients with adjudicated preeclampsia and a cohort consisting of twice as many healthy pregnant female patients defined as having an uneventful pregnancy outcome. Preeclampsia disproportionally affects Black women 60% more of the time compared to White women. The Atellica IM assays, Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) and Placental Growth Factor (PlGF), used as a ratio proved to aid in diagnosing preeclampsia and represents findings including a larger demographic of affected women. Methods Samples with a clinical preeclampsia diagnosis following ACOG guidelines were collected (N=695, clinical trial samples) and tested using the Atellica IM sFlt-1 and PlGF assays on the Atellica IM analyzer. Participants were 30 years of age on average (range=18-49), 23% were Black, and 27% were Hispanic. Normal values of sFlt-1, PlGF, and the sFlt-1/PlGF ratio for completed weeks of gestation were reported for 452 patients with uneventful pregnancy outcome, not diagnosed with any form of PE/eclampsia/HELLP/IUGR. The cutoff ratios were derived for both an early gestational group and late gestational group 95% confidence intervals for percent agreement were estimated using an sFlt-1/PlGF ratio derived from clinical data and optimized using an AUROC curve with early gestational age rule-out and rule-in sensitivities of >=89% and >=81% and specificities of >=90% and >=97%, respectively and late gestational age rule-out and rule-in sensitivities of >=84% and >=68% and specificities of >=50% and >=92%, respectively. For each of the 2 gestational phase groups, 2 independent cutoffs framing an equivocal zone were determined: the first cutoff with focus on maximizing high sensitivity, and the second focusing on maximizing high specificity, as specified. Results For patients within the early gestational period, the sFlt-1/PlGF ratio cutoffs at <=33 and >=85 resulted in a sensitivity/specificity of 89.6%/91.7% for rule-out and 83.7%/98.0% for rule-in, respectively; corresponding to an LR- of 0.03 (95% CI, 0.02–0.04) and an LR+ of 160.5 (95% CI, 22.6-1140). Further, when combining the cutoffs of <=33/>=85, a sensitivity of 89.6% and a specificity of 98% were reached. After 34 weeks gestation, the late gestation cutoffs at <=33 and >=110 yielded a sensitivity/specificity of 86.1%/81.4% for rule-out and 62.0%/97.0% for rule-in, respectively; corresponding to an LR- of 0.03 (95% CI, 0.02–0.05) and LR+ of 13.5 (95% CI, 5.9–30.6). And when combining the cutoffs of <=33/>=110, a sensitivity of 86.1% and a specificity of 97% were reached. Conclusions This study is the first to provide gestational-specific rule-in and rule-out cutoffs in a large multi-site study with a large proportion of Black and Hispanic pregnant females. The approach to use multiple cutoffs for the early and late gestational phase enhances the diagnostic accuracy of the sFlt-1/PlGF ratio as a diagnostic tool for preeclampsia.
No takes yet. Share an insight, caveat, or question.
Love et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: